These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

946 related items for PubMed ID: 20124563

  • 1. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B.
    BMJ; 2010 Feb 02; 340():c147. PubMed ID: 20124563
    [Abstract] [Full Text] [Related]

  • 2. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov 02; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 3. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A.
    Br J Dermatol; 2007 Jan 02; 156(1):138-42. PubMed ID: 17199580
    [Abstract] [Full Text] [Related]

  • 4. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb 02; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, Furst DE.
    Arthritis Rheum; 2008 Jul 02; 58(7):1921-30. PubMed ID: 18576334
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Jul 02; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun 02; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 8. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr 02; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 9. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
    FitzGerald O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, Nab H, Molta C.
    Ann Rheum Dis; 2012 Mar 02; 71(3):358-62. PubMed ID: 21989542
    [Abstract] [Full Text] [Related]

  • 10. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
    Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.
    J Eur Acad Dermatol Venereol; 2012 Nov 02; 26(11):1436-43. PubMed ID: 22035157
    [Abstract] [Full Text] [Related]

  • 11. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study 314 Investigators.
    Ann Rheum Dis; 2006 Dec 02; 65(12):1572-7. PubMed ID: 16968715
    [Abstract] [Full Text] [Related]

  • 12. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.
    J Am Acad Dermatol; 2007 Apr 02; 56(4):598-603. PubMed ID: 17113190
    [Abstract] [Full Text] [Related]

  • 13. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 14. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ.
    Lancet; 2000 Jul 29; 356(9227):385-90. PubMed ID: 10972371
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.
    J Am Acad Dermatol; 2006 Mar 29; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [Abstract] [Full Text] [Related]

  • 16. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.
    Br J Dermatol; 2005 Dec 29; 153(6):1192-9. PubMed ID: 16307657
    [Abstract] [Full Text] [Related]

  • 17. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
    Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF.
    J Rheumatol; 2010 Jun 29; 37(6):1221-7. PubMed ID: 20395648
    [Abstract] [Full Text] [Related]

  • 18. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
    Prinz JC, Fitzgerald O, Boggs RI, Foehl J, Robertson D, Pedersen R, Molta CT, Freundlich B.
    J Eur Acad Dermatol Venereol; 2011 May 29; 25(5):559-64. PubMed ID: 20840349
    [Abstract] [Full Text] [Related]

  • 19. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
    Campione E, Mazzotta A, Paternò EJ, Diluvio L, Prinz JC, Chimenti S.
    Acta Derm Venereol; 2009 May 29; 89(3):288-91. PubMed ID: 19479128
    [Abstract] [Full Text] [Related]

  • 20. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
    De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S.
    J Dermatolog Treat; 2006 May 29; 17(6):355-8. PubMed ID: 17853309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.